GetTopicDetailResponse(id=5063388932e, topicName=吉利德, introduction=吉利德, content=null, image=null, comments=4, allHits=2334, url=https://h5.medsci.cn/topic?id=38893, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=14232, tagList=[TagDto(tagId=14232, tagName=吉利德)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=888466, encodeId=993388846663, content=<a href='/topic/show?id=cf292341925' target=_blank style='color:#2F92EE;'>#乙肝#</a>神藥TAF國(guó)內(nèi)能仿制藥了？這下子<a href='/topic/show?id=5063388932e' target=_blank style='color:#2F92EE;'>#吉利德#</a>要降價(jià)了哦。這個(gè)藥基本能將乙肝控制到正常狀態(tài), objectTitle=“乙肝神藥”TAF國(guó)內(nèi)首仿或上市在即, objectType=article, longId=201234, objectId=589f201234a1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020925/1601029106346_5295905.jpg, objectUrl=/article/show_article.do?id=589f201234a1, replyNumber=0, likeNumber=7, createdTime=2020-09-26, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=589f201234a1, moduleTitle=“乙肝神藥”TAF國(guó)內(nèi)首仿或上市在即, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=589f201234a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=885353, encodeId=3c96885353e7, content=<a href='/topic/show?id=5063388932e' target=_blank style='color:#2F92EE;'>#吉利德#</a>到處收購(gòu), objectTitle=210億美元！吉利德收購(gòu)Immunomedics，將“first-in-class”抗體偶聯(lián)藥物收入囊中, objectType=article, longId=200683, objectId=f79c20068376, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020914/1600095157102_2119349.jpg, objectUrl=/article/show_article.do?id=f79c20068376, replyNumber=0, likeNumber=261, createdTime=2020-09-15, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f79c20068376, moduleTitle=210億美元！吉利德收購(gòu)Immunomedics，將“first-in-class”抗體偶聯(lián)藥物收入囊中, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f79c20068376)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=885170, encodeId=c3c48851e0b6, content=<a href='/topic/show?id=5063388932e' target=_blank style='color:#2F92EE;'>#吉利德#</a>太有錢了，到處收購(gòu)，以前收購(gòu)了CAR-T公司，現(xiàn)在又收購(gòu)Immunomedics公司，基本全面進(jìn)入<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#腫瘤#</a>領(lǐng)域了, objectTitle=吉利德宣布將以210億美元收購(gòu)癌癥藥物生產(chǎn)商Immunomedics, objectType=article, longId=200661, objectId=f19a2006611d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020914/1600042287228_5268530.jpeg, objectUrl=/article/show_article.do?id=f19a2006611d, replyNumber=0, likeNumber=283, createdTime=2020-09-14, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f19a2006611d, moduleTitle=吉利德宣布將以210億美元收購(gòu)癌癥藥物生產(chǎn)商Immunomedics, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f19a2006611d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=801423, encodeId=bf2680142326, content=<a href='/topic/show?id=5063388932e' target=_blank style='color:#2F92EE;'>#吉利德#</a>這家公司在感染你確實(shí)是很牛叉。, objectTitle=吉利德科學(xué)：長(zhǎng)效HIV-1衣殼抑制劑Lenacapavir（GS-6207）臨床表現(xiàn)良好, objectType=article, longId=197123, objectId=dc3519e123a3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202076/1593995479818_5295902.jpeg, objectUrl=/article/show_article.do?id=dc3519e123a3, replyNumber=0, likeNumber=217, createdTime=2020-07-06, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc3519e123a3, moduleTitle=吉利德科學(xué)：長(zhǎng)效HIV-1衣殼抑制劑Lenacapavir（GS-6207）臨床表現(xiàn)良好, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=dc3519e123a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
